FindTrial
Sign In

To determine role of Secreted frizzled-related protein 4 (SFRP4), a cancer protective protein in malignancies for determining aggressiveness of tumors.

Determining role of Secreted frizzled related protein 4 (SFRP4), a soluble WNT antagonist multifunctional protein in malignancies for determining prognostic factors of tumors. - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/04/065389
Enrollment
30
Registered
2024-04-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C768- Malignant neoplasm of other specified ill-defined sites

Interventions

Intervention1: NIL: NIL

Sponsors

DY Patil University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients with malignancy will be eligible for participation in the study provided they give consent for participation

Exclusion criteria

Exclusion criteria: Non malignant cases will be excluded

Design outcomes

Primary

MeasureTime frame
Association of Secreted frizzled related protein 4 with cancer prognosisTimepoint: At diagnosis, immediately after treatment, 3 months, 6 months, 12 months and after 2 years. Follow up for each malignancy will be as per the standard protocol and no extra follow up will be done for study purpose unless clinically indicated.—

Secondary

MeasureTime frame
Determining benefit of developing Secreted frizzled related protein 4 analogues for clinical use.Timepoint: At the end of study—

Countries

India

Contacts

Public ContactPrasant Chandra

DY Patil Medical College

dr.prashantchandra@gmail.com8446539602

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026